MOTS-c and Metabolism: The Evidence So Far
MOTS-c is the most scientifically interesting peptide on this part of the site and one of the least proven in people. Both halves of that sentence are worth taking seriously, and they are usually reported separately.
The interesting half: it is encoded not in the nuclear genome but inside mitochondrial DNA, which overturned a reasonable assumption about what mitochondria do. The unproven half: nearly everything known about what it does comes from cultured cells and from mice.
What it is
MOTS-c stands for mitochondrial open reading frame of the twelve-S ribosomal RNA type-c. It is a short peptide, sixteen amino acids, and its sequence is written inside the mitochondrial genome rather than the nuclear one.
That is the part that made it a genuine finding rather than another entry in a supplement catalog. Mitochondria were understood to encode a small set of proteins for their own respiratory machinery. A peptide encoded there that leaves the mitochondrion, travels in the bloodstream and acts on distant tissue implies a signaling role — the mitochondrion reporting its state to the rest of the body. It was described by a research group at the University of Southern California in 2015.
MOTS-c is measurable in human plasma, and circulating levels have been reported to decline with age. That observation is what turned a molecular-biology finding into a metabolic hypothesis.
How it is thought to work
The proposed mechanism runs through a pathway most readers will have met under another name.
MOTS-c appears to interfere with the folate-methionine cycle, causing an intermediate to accumulate, which in turn activates AMP-activated protein kinase — AMPK. AMPK is the cell's low-energy sensor. When it is switched on, cells shift toward consuming fuel rather than storing it: glucose uptake rises, fatty acid oxidation rises, and growth-oriented pathways are dialed down.
That is the same pathway metformin is understood to act on, by a different route, and the same pathway sustained exercise activates. Which is why MOTS-c attracts the comparisons it does, and why the claims attached to it tend to run well ahead of the data. The exercise framing gets its own page for that reason.
What the animal work shows
This is where the substance of the research lives, and it is not trivial.
In mice, administered MOTS-c has been reported to improve insulin sensitivity, to resist diet-induced obesity and the insulin resistance that comes with it, and to reverse some age-related decline in physical performance in older animals. There is also work on MOTS-c in bone metabolism and on skeletal muscle, which matters for how the compound was framed in its regulatory nomination.
Those are real experiments with a coherent mechanism. They are also mice. Metabolic interventions in rodents have an unusually poor record of translating, because a mouse's metabolism, lifespan, thermoregulation and diet differ from a person's in ways that matter specifically for this kind of question.
Where the human data stops
Honestly: close to the beginning.
The human evidence is largely observational. Plasma MOTS-c rises acutely with exercise in people. Levels differ by age and, in some cohorts, by metabolic status. A naturally occurring variant in the MOTS-c sequence, found in East Asian populations, has been associated in Japanese cohorts with metabolic risk and with longevity.
Every one of those is an association. None of them tells you what happens when you give MOTS-c to a person.
There has been at least one early-phase clinical program using a MOTS-c analogue, developed by a biotechnology company and taken into first-in-human testing for metabolic indications. It did not progress to large later-stage trials.
So the accurate statement is that MOTS-c is a compound with an interesting mechanism, supportive animal work, suggestive human observations, and no controlled trial establishing a clinical benefit in people. We are not going to dress that up.
What the advisory committee was looking at
In July 2026, the FDA's Pharmacy Compounding Advisory Committee considered MOTS-c among a group of nominated peptides, in the context of obesity and osteoporosis — the indications it was put forward for. The committee recommended it for the 503A Bulks List on a seven to five vote with two abstentions. FDA staff had recommended against inclusion.
Three qualifications belong with that, in the same breath.
It was close. A seven to five vote with two abstentions is a divided committee, not a consensus.
It is a recommendation, not a decision. Formal addition to the 503A Bulks List requires notice-and-comment rulemaking, and as of September 2026 that has not been completed for any of the peptides considered at that meeting.
And the committee was deciding a question about compounding eligibility, not about efficacy. Nothing in that vote is a finding that MOTS-c works for obesity, for osteoporosis, or for anything else. It is not an FDA-approved drug. The same committee declined to recommend one of the peptides before it, which is covered on the DSIP regulatory page.
What we would actually do about insulin resistance
If the reason MOTS-c caught your eye is a fasting glucose that has been creeping, a waist that has changed, or an HbA1c in the range nobody calls diabetes but nobody calls normal either, then the useful work is available now and it is not experimental.
Measure it properly: fasting insulin alongside glucose, HbA1c, a lipid panel with ApoB, liver enzymes, and body composition rather than weight alone. That is a baseline panel question. Then resistance training, protein intake, sleep, alcohol, and — where it fits the picture and the person — a medication with completed outcome trials behind it, such as semaglutide.
MOTS-c may eventually have a place. Today it has a mechanism and a literature, and those are not the same as a result.
Frequently asked questions
It has been reported to do so in mice. No controlled human trial has established that effect in people, so we make no such claim.
It is encoded in mitochondrial DNA rather than the nuclear genome, which is unusual and scientifically significant. That does not by itself tell you anything about clinical benefit.
Mostly observational. Plasma levels rise with exercise and vary with age, and a natural sequence variant has been associated with metabolic outcomes in Japanese cohorts. An early-phase program with a MOTS-c analogue was run and did not advance to large trials.
No. The committee was considering eligibility for pharmacy compounding, not effectiveness. It recommended MOTS-c seven to five with two abstentions, and that recommendation still requires rulemaking to take effect.
Both are understood to activate AMPK, by different routes. Metformin has decades of trials and outcome data. MOTS-c has neither, so the comparison describes a pathway, not an equivalence.
Get measured — fasting insulin with glucose, HbA1c, ApoB, liver enzymes, body composition. Then resistance training, protein, sleep and alcohol, and a medication with finished outcome trials if one fits.
Where this fits in your plan
Read MOTS-c and exercise next, because that is where the claims get loudest. The peptide therapy overview covers how we weigh this category, and the baseline panel is where a metabolic question properly starts.
We measure first. Then we act.
References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015;21:443–454.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications 2021;12:470.
- Kumagai H, Natsume T, Kim S-J, et al. The MOTS-c K14Q variant and metabolic outcomes.
- Merry TL, Chan A, Woodhead JST, et al. Mitochondrial-derived peptides in energy metabolism. American Journal of Physiology — Endocrinology and Metabolism 2020.
- FDA. Pharmacy Compounding Advisory Committee, meeting of 23–24 July 2026 — MOTS-c nomination and vote.
- Back toMOTS-c
- MOTS-c and exerciseMOTS-c is marketed as exercise in a bottle. Where the exercise-mimetic idea came from, what it gets wrong, and why nothing here replaces training.Read
- DSIP regulatory statusIn July 2026 an FDA advisory committee recommended six peptides for the 503A list and declined to recommend DSIP. What that vote was, and what it was not.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.